1. Proof of the technology advantage
“Canatu reports over 97% EUV transmission for uncoated CNT membranes, and competitors such as Mitsui Chemicals have presented high transmission figures for their own CNT membranes as well. Since transmission depends largely on membrane thickness, where does Canatu’s advantage show up in practice? For example, do you have data showing that Canatu-based membranes, once coated, last longer at the same transmission, or need a thinner coating for the same lifetime?”
2. Royalty protection and customers’ own IP
“Large chipmakers such as TSMC have their own patents for reactor-based CNT membrane production, and Canatu’s earliest dry-deposition patent families, filed in 2007 and 2010, reach the end of their standard 20-year term around 2027–2030. How are Canatu’s royalty rights secured contractually, and what protects the CNT100 SEMI business after those early patents expire, whether newer patents, trade secrets or process know-how?”
3. Royalty economics
“In general terms, how is the royalty structured: a fixed amount per membrane, or a share of the pellicle’s price? Do the agreements include minimum volumes? And are the consumables the reactor needs specific to Canatu, or could customers in principle source them from other suppliers?”